# MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

> **NCT03962543** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany** · enrollment: 114 (actual)

## Conditions studied

- Plexiform Neurofibroma
- Neurofibromatosis Type 1 (NF1)

## Interventions

- **DRUG:** Mirdametinib (PD-0325901) oral capsule or dispersible tablet

## Key facts

- **NCT ID:** NCT03962543
- **Lead sponsor:** SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-29
- **Primary completion:** 2023-09-20
- **Final completion:** 2028-12-22
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962543, "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03962543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*